Summary
Leveraging endogenous tumor-resident T-cells for immunotherapy using bispecific antibodies (BsAb) targeting CD20 and CD3 has emerged as a promising therapeutic strategy for patients with B-cell non-Hodgkin lymphomas. However, features associated with treatment response or resistance are unknown. To this end, we analyzed data from patients treated with epcoritamab-containing regimens in the EPCORE NHL-2 trial (NCT04663347). We observed downregulation of CD20 expression on B-cells following treatment initiation both in progressing patients and in patients achieving durable complete responses (CR), suggesting that CD20 downregulation does not universally predict resistance to BsAb-based therapy. Single-cell immune profiling of tumor biopsies obtained following one cycle of therapy revealed substantial clonal expansion of cytotoxic CD4+ and CD8+ T-cells in patients achieving CR, and an expansion of follicular helper and regulatory CD4+ T-cells in patients whose disease progressed. These results identify distinct tumor-resident T-cell profiles associated with response or resistance to BsAb therapy.
Competing Interest Statement
L.F. Has received research funding from Genmab A/S, AbbVie, Inc., F. Hoffmann-La Roche AG, Genentech Inc., Innate Pharma S.A.; has provided consulting services for Genmab A/S, AbbVie, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Evolveimmune Therapeutics, Inc., Sanofi, S.A.; has served as an advisor for AbbVie, Inc., Seagen, Inc., Ipsen Biopharmaceuticals, Inc., ADC therapeutics S.A.; and has received travel reimbursement from Genmab A/S, AbbVie, Inc. S.A.V. previously served as an advisor for Immunai, has provided consulting services for ADT Therapeutics and Koch Disruptive Technologies, and has received funding from BMS. G.S. has received financial compensation for consulting services in the last 12 months from: Abbvie, Atb Therapeutics, Beigene, BMS, Genentech/Roche, Genmab, Janssen, Innate Pharma, Incyte, Ipsen, Kite/Gilead, Merck, Modex, Molecular Partners, Novartis, Nurix, Orna Therapeutics, and Treeline. He is a shareholder of Owkin. He has received research support from Abbvie, Genentech, Genmab, Janssen, Ipsen, and Nurix, which his institution managed.
Clinical Trial
NCT04663347
Funding Statement
This work was supported by a Steven Greenberg Lymphoma Grant and a Priority Research Grant from the Lymphoma Research Foundation (S.A.V.) as well as MSKCC Core Grant P30 CA008748. We thank Dr. Andrew Steele for his insightful input.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was assigned IRB Protocol #21-164, was approved as per 45 CFR 46.111 and/or 21 CFR 56.111 by the MSKCC Institutional Review Board/Privacy Board-A initially on April 5, 2021 and conducted in accordance with the principles outlined in the Declaration of Helsinki. Approval of the study with amendments was most recently issued on June 7, 2024.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
